Citation Impact
Citing Papers
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
A comparison of recombinant Hirudin with Heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators
1996
The gut microbiota and host health: a new clinical frontier
2015 Standout
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use
2008
Acute Coronary Care in the Elderly, Part I
2007
New P2Y12Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention
2010
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?
1999
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38
2009
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
2013 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Nucleotide signalling during inflammation
2014 StandoutNature
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
2015
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
2003
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing
2009
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
2008
Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy
2011
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome
2009
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
2009
Atherosclerosis: current pathogenesis and therapeutic options
2011 Standout
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
2009
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients
2013 StandoutNobel
Unstable Angina Pectoris
2000
Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality Benefit From Coronary Revascularization in Acute Coronary Syndromes
2006
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.
2000
Platelet Activation and Atherothrombosis
2007 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
2011
Bladder cancer
2016 Standout
Integrated Analysis of Pharmacokinetic Data Across Multiple Clinical Pharmacology Studies of Prasugrel, a New Thienopyridine Antiplatelet Agent
2010
Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes
2008
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention
2009
Antithrombotic Therapy in the Elderly
2010
Heparin and Low-Molecular-Weight Heparin
1998
How were new medicines discovered?
2011 Standout
A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes
2004
Guidelines for Percutaneous Coronary Interventions
2005
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on‐treatment platelet reactivity
2011
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
2008
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
2009
Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study was supported by Centocor, Inc., Malvern, Pennsylvania.
1997
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
2003
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
2009
Improving Primary Care for Patients With Chronic Illness
2002 Standout
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial
2011
Improving Primary Care for Patients With Chronic Illness
2002 Standout
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
2008
The Determinants of Activated Partial Thromboplastin Time, Relation of Activated Partial Thromboplastin Time to Clinical Outcomes, and Optimal Dosing Regimens for Heparin Treated Patients with Acute Coronary Syndromes: A Review of GUSTO-IIb
2002
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI
2000 Standout
Prolonged Beneficial Effects of a Home-Based Intervention on Unplanned Readmissions and Mortality Among Patients With Congestive Heart Failure
1999
Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention
2010
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays
2013
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
2000 Standout
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes
2004
Efficacy of Unfractionated Heparin, Low Molecular Weight Heparin and Both Combined for Releasing Total and Free Tissue Factor Pathway Inhibitor
1998
Antiplatelet agents for the treatment and prevention of atherothrombosis
2011
Hemorrhagic Complications of Anticoagulant Treatment
2004
Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation and Arterial Embolism After Acute Anterior Myocardial Infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study 11This study was supported by grants from the Norwegian Council on Cardiovascular Diseases, Oslo, Norway and Pharmacia AB, Stockholm, Sweden.
1997
Multidisciplinary strategies for the management of heart failure patients at high risk for admission
2004 Standout
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding
2010 Standout
Elevated Levels of C-Reactive Protein at Discharge in Patients With Unstable Angina Predict Recurrent Instability
1999
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease
1997
Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease
2000
Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction
1999
Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes
2003
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
2003
Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients
2004 Standout
Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
2009
Acute Coronary Syndromes
1998
Guidelines for the Primary Prevention of Stroke
2014 Standout
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
2006
Applicability of Cardiac Troponin T and I for Early Risk Stratification in Unstable Coronary Artery Disease
1997
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Impact of Early Coronary Artery Bypass Graft in an Unselected Acute Coronary Syndrome Patient Population
2006
Inflammation and Atherosclerosis
2002 Standout
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
2010
Sudden Cardiac Death
1998 Standout
2012 Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations
2012
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
2007
Prasugrel
2009
The Biological Basis for Cardiac Repair After Myocardial Infarction
2016 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
2000 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction
1999
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
2013
Inflammatory Markers and Onset of Cardiovascular Events
2003 Standout
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Influence of Renal Function on the Effects of Early Revascularization in Non-ST-Elevation Myocardial Infarction
2009
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Prognostic Utility of Novel Biomarkers of Cardiovascular Stress
2012
Oral Delivery of Anticoagulant Doses of Heparin
1998
ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2012
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of Lars Wallentin being referenced
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS
2004
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)
1997
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction
2007
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction—the ASSENT Plus study
2003
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
2008